Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
8.68
-0.16 (-1.81%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Viatris Revenue
In the year 2024, Viatris had annual revenue of $14.74B, down -4.46%. Viatris had revenue of $3.53B in the quarter ending December 31, 2024, a decrease of -8.06%.
Revenue (ttm)
$14.74B
Revenue Growth
-4.46%
P/S Ratio
0.70
Revenue / Employee
$460,603
Employees
32,000
Market Cap
10.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.74B | -687.60M | -4.46% |
| Dec 31, 2023 | 15.43B | -835.80M | -5.14% |
| Dec 31, 2022 | 16.26B | -1.62B | -9.08% |
| Dec 31, 2021 | 17.89B | 5.94B | 49.73% |
| Dec 31, 2020 | 11.95B | 445.50M | 3.87% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
VTRS News
- 1 day ago - Viatris to Report First Quarter 2025 Financial Results on May 8, 2025 - PRNewsWire
- 1 day ago - Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman - GlobeNewsWire
- 2 days ago - If you love dividend stocks, check out these 11 companies with room to boost their hefty payouts - Market Watch
- 14 days ago - Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility - Hagens Berman - Accesswire
- 14 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Shareholders to Reach Out - Accesswire
- 15 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PRNewsWire
- 15 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 16 days ago - Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire